# A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients

> **NCT03284177** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 55 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Calcium (13C)Carbonate
- **DRUG:** Gastric acid inhibitors
- **OTHER:** Gastric pH monitoring

## Key facts

- **NCT ID:** NCT03284177
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-31
- **Primary completion:** 2018-12-04
- **Final completion:** 2018-12-04
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284177, "A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03284177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*